SMT201600108B - Derivato di pirazochinolina come inibitori di pde9 - Google Patents

Derivato di pirazochinolina come inibitori di pde9

Info

Publication number
SMT201600108B
SMT201600108B SM201600108T SM201600108T SMT201600108B SM T201600108 B SMT201600108 B SM T201600108B SM 201600108 T SM201600108 T SM 201600108T SM 201600108 T SM201600108 T SM 201600108T SM T201600108 B SMT201600108 B SM T201600108B
Authority
SM
San Marino
Prior art keywords
pirazochinolin
pde9
inhibitors
derivatives
pirazochinolin derivatives
Prior art date
Application number
SM201600108T
Other languages
English (en)
Italian (it)
Inventor
Yoshihiko Norimine
Kunitoshi Takeda
Koji Hagiwara
Yuichi Suzuki
Yuki Ishihara
Nobuaki Sato
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SMT201600108B publication Critical patent/SMT201600108B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201600108T 2011-10-07 2016-04-14 Derivato di pirazochinolina come inibitori di pde9 SMT201600108B (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161544860P 2011-10-07 2011-10-07
US201161550623P 2011-10-24 2011-10-24
US201161558110P 2011-11-10 2011-11-10
US201161580903P 2011-12-28 2011-12-28
PCT/JP2012/075748 WO2013051639A1 (fr) 2011-10-07 2012-10-04 Dérivé de pyrazoloquinoline

Publications (1)

Publication Number Publication Date
SMT201600108B true SMT201600108B (it) 2016-04-29

Family

ID=48043792

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600108T SMT201600108B (it) 2011-10-07 2016-04-14 Derivato di pirazochinolina come inibitori di pde9

Country Status (33)

Country Link
US (2) US8563565B2 (fr)
EP (1) EP2769980B1 (fr)
JP (1) JP5546693B2 (fr)
KR (1) KR101943680B1 (fr)
CN (1) CN103930423B (fr)
AR (1) AR088235A1 (fr)
AU (1) AU2012319549B2 (fr)
BR (1) BR112014007912B1 (fr)
CA (1) CA2861795C (fr)
CL (1) CL2014000821A1 (fr)
CO (1) CO6910200A2 (fr)
CY (1) CY1117427T1 (fr)
DK (1) DK2769980T3 (fr)
ES (1) ES2568015T3 (fr)
HK (1) HK1199018A1 (fr)
HR (1) HRP20160273T1 (fr)
HU (1) HUE028555T2 (fr)
IL (1) IL231650A (fr)
IN (1) IN2014CN02463A (fr)
JO (1) JO3116B1 (fr)
ME (1) ME02394B (fr)
MX (1) MX358149B (fr)
MY (1) MY167698A (fr)
PE (1) PE20141557A1 (fr)
PL (1) PL2769980T3 (fr)
RS (1) RS54702B1 (fr)
RU (1) RU2605096C2 (fr)
SG (1) SG11201400717QA (fr)
SI (1) SI2769980T1 (fr)
SM (1) SMT201600108B (fr)
TW (1) TWI562993B (fr)
WO (1) WO2013051639A1 (fr)
ZA (1) ZA201402439B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN02829A (fr) 2011-10-10 2015-09-11 Lundbeck & Co As H
JP6244353B2 (ja) 2013-04-05 2017-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジニルピラゾロキノリン化合物
CA2907971C (fr) * 2013-04-05 2020-12-29 Eisai R&D Management Co., Ltd. Sel de derive de pyrazoloquinoline et son cristal
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
WO2016021192A1 (fr) * 2014-08-08 2016-02-11 Eisai R&D Management Co., Ltd. Procédé pour la préparation de (s)-(tétrahydrofurann-3-yl)hydrazine
MX2018000283A (es) 2015-07-07 2018-11-22 H Lundbeck As Inhibidores de fde9 con estructura basica de imidazotriazinona y estructura basica de imidazopirazinona en el tratamiento de enfermedades perifericas.
WO2017046606A1 (fr) * 2015-09-18 2017-03-23 Redx Pharma Plc Composés antibactériens
CN107056690A (zh) * 2017-03-22 2017-08-18 上海康鹏科技有限公司 一种6‑溴吡啶‑3‑甲醛的制备方法
RU2019135261A (ru) 2017-06-01 2021-07-09 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор pde9
WO2018221551A1 (fr) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique contenant un dérivé de pyrazoloquinoline pour traiter la maladie à corps de lewy
CN110603040B (zh) * 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和多奈哌齐的痴呆治疗剂
CN110603039B (zh) * 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
CN111630042A (zh) 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
CA3110680A1 (fr) * 2018-08-31 2020-03-05 Imara Inc. Inhibiteurs de pde9 pour le traitement de la drepanocytose
CN114126619B (zh) * 2019-05-09 2024-03-15 范因斯坦医学研究院 用于合成肽模拟物的化合物
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
EP3965792A4 (fr) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research Antagoniste de hmgb1
CA3139104A1 (fr) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Thiosemicarbazates et leurs utilisations
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
CR20220584A (es) * 2020-04-16 2023-02-15 Incyte Corp Inhibidores de kras tricíclicos fusionados
WO2021231526A1 (fr) 2020-05-13 2021-11-18 Incyte Corporation Composés de pyrimidine fusionnés utilisés comme inhibiteurs de kras
EP4172153A1 (fr) 2020-06-30 2023-05-03 Bayer Aktiengesellschaft Hétéroaryloxypyridines substituées, leurs sels et leur utilisation comme agents herbicides
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426734C2 (ru) * 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (fr) * 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. Inhibiteurs de chk-1
AU2006289838B2 (en) * 2005-09-15 2011-08-18 Aska Pharmaceutical Co., Ltd. Heterocyclic compound, and production process and use thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
KR101563103B1 (ko) * 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
GEP20125405B (en) 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8357688B2 (en) 2009-03-05 2013-01-22 Astellas Pharma Inc. Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors
PL2414363T3 (pl) 2009-03-31 2014-06-30 Boehringer Ingelheim Int Pochodne 1-heterocyklilo-1,5-dihydro-pirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako modulatorów PDE9A
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
CN103097383B (zh) * 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
KR20140082684A (ko) 2014-07-02
PE20141557A1 (es) 2014-11-15
MY167698A (en) 2018-09-21
CO6910200A2 (es) 2014-03-31
BR112014007912B1 (pt) 2022-06-07
IL231650A0 (en) 2014-05-28
CN103930423A (zh) 2014-07-16
CY1117427T1 (el) 2017-04-26
CN103930423B (zh) 2015-09-16
KR101943680B1 (ko) 2019-01-29
TWI562993B (en) 2016-12-21
BR112014007912A2 (pt) 2017-04-04
EP2769980A1 (fr) 2014-08-27
HRP20160273T1 (hr) 2016-04-08
DK2769980T3 (en) 2016-04-11
JPWO2013051639A1 (ja) 2015-03-30
JP5546693B2 (ja) 2014-07-09
US20130143907A1 (en) 2013-06-06
SI2769980T1 (sl) 2016-08-31
ES2568015T3 (es) 2016-04-27
PL2769980T3 (pl) 2016-07-29
CA2861795C (fr) 2018-12-04
EP2769980A4 (fr) 2015-02-25
HK1199018A1 (zh) 2015-06-19
CA2861795A1 (fr) 2013-04-11
RU2014112931A (ru) 2015-11-20
US8563565B2 (en) 2013-10-22
CL2014000821A1 (es) 2014-07-25
ME02394B (fr) 2016-09-20
ZA201402439B (en) 2015-03-25
AR088235A1 (es) 2014-05-21
HUE028555T2 (en) 2016-12-28
MX2014003800A (es) 2014-07-28
IN2014CN02463A (fr) 2015-06-19
EP2769980B1 (fr) 2016-02-03
RU2605096C2 (ru) 2016-12-20
WO2013051639A1 (fr) 2013-04-11
IL231650A (en) 2016-05-31
AU2012319549A1 (en) 2014-04-24
NZ622594A (en) 2015-06-26
SG11201400717QA (en) 2014-06-27
MX358149B (es) 2018-08-07
RS54702B1 (en) 2016-08-31
TW201321379A (zh) 2013-06-01
JO3116B1 (ar) 2017-09-20
US20130296352A1 (en) 2013-11-07
AU2012319549B2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
SMT201600108B (it) Derivato di pirazochinolina come inibitori di pde9
CY2023023I1 (el) Παραγωγα λακταμης χρησιμα ως αναστολεις μεταλλαγμενης idh1
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
SMT201700109B (it) Inibitori di istone demetilasi
SMT201600238B (it) Inibitori di protein chinasi
SMT201700094B (it) Composto di pirazina carbossammide
SMT201500270B (it) Derivati di pirrolotriazinone come inibitori di pi3k
SMT201600272B (it) Diidropiridinoni e piperidinoni arilici come inibitori di mgat2
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
SMT201600020B (it) Derivati di benzilammina come inibitori di callicreina plasmatica
SMT201500271B (it) Inibitori di neprilisina
SMT201600153B (it) Derivato di azolo
CO6960542A2 (es) Polimorfos de inhibidores de cinasas
CO6920296A2 (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CO6970602A2 (es) Inhibidores de quinasa
CO7010824A2 (es) Inhibidores de aplicación viral
SMT201600114B (it) Inibitori di beta-secretasi
CO6870035A2 (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
DK2710007T3 (da) Kinasehæmmere
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
CR20130192A (es) Derivados de bencimidazol como inhibidores de cinasa p13
CO7020913A2 (es) Inhibidores de pde9 con estructura básica de imidazotriazinona